Compare BKSY & IRWD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BKSY | IRWD |
|---|---|---|
| Founded | 2013 | 1998 |
| Country | United States | United States |
| Employees | 340 | N/A |
| Industry | Radio And Television Broadcasting And Communications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 726.7M | 663.6M |
| IPO Year | N/A | 2009 |
| Metric | BKSY | IRWD |
|---|---|---|
| Price | $36.35 | $4.60 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 4 | 3 |
| Target Price | ★ $28.50 | $7.67 |
| AVG Volume (30 Days) | ★ 1.9M | 1.6M |
| Earning Date | 05-07-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 1400.00 |
| EPS | N/A | ★ 0.15 |
| Revenue | N/A | ★ $298,276,000.00 |
| Revenue This Year | $27.03 | $57.95 |
| Revenue Next Year | $29.21 | $4.39 |
| P/E Ratio | ★ N/A | $29.60 |
| Revenue Growth | N/A | ★ 8.88 |
| 52 Week Low | $8.29 | $0.55 |
| 52 Week High | $42.75 | $5.78 |
| Indicator | BKSY | IRWD |
|---|---|---|
| Relative Strength Index (RSI) | 57.64 | 64.35 |
| Support Level | $16.87 | $3.07 |
| Resistance Level | $42.75 | $5.67 |
| Average True Range (ATR) | 3.46 | 0.26 |
| MACD | -0.48 | 0.04 |
| Stochastic Oscillator | 50.50 | 98.87 |
BlackSky Technology Inc is a provider of real-time geospatial intelligence. The company delivers on-demand, high-frequency imagery, monitoring, and analytics of some of the critical and strategic locations, economic assets, and events in the world. It designs, owns, and operates one of the industry's low earth orbit (LEO) small satellite constellations, optimized to capture imagery cost-efficiently where and when its customers need it. its Spectra AI software platform processes data from BlackSky's constellation and other third-party sensors to develop the critical insights and analytics that provide its customers with the actionable intelligence. Geographically, the company operates in North America, the Middle East, Asia, and Others.
Ironwood Pharmaceuticals Inc is a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal, or GI, and rare diseases. It is focused on the development and commercialization of inventive product opportunities in areas of unmet need, leveraging its demonstrated expertise and capabilities in GI and rare diseases. LINZESS is its commercial product. LINZESS is also available for the treatment of adults with IBS-C or CIC in Mexico, adults with IBS-C or chronic constipation in Japan, and adults with IBS-C in China. Linaclotide is available under the trademarked name CONSTELLA for the treatment of adults with IBS-C or CIC and pediatric patients ages 6-17 years old with FC in Canada, and to adults with IBS-C in certain European countries.